使用警語:中文譯文來源為 AI 翻譯,僅供參考,實際內容請以英文原文為主
Operator
Operator
Good day, everyone, and welcome to today's DexCom Second Quarter Year 2008 Earnings Conference Call. Please be aware that today's conference is being recorded. At this time, I would like to turn the conference over to Mr. Terry Gregg. Please go ahead, sir.
各位大家好,歡迎參加今天的 DexCom 2008 年第二季財報電話會議。請注意,今天的會議將被錄音。此刻,我想將會議交給 Terry Gregg 先生。先生,請開始。
Terry Gregg - President and CEO
Terry Gregg - President and CEO
Thank you, operator, and thanks for joining us today for the second quarter update. Joining me today is Steve Pacelli, our Senior Vice President Corporate Affairs; Jess Roper, Vice President, Chief Financial Officer.
謝謝接線員,也感謝各位今天加入我們的第二季更新。今天與我一同出席的有:公司事務資深副總裁 Steve Pacelli;副總裁兼財務長 Jess Roper。
Let's start off with Steve on a safe-harbor review.
我們先請 Steve 進行安全港聲明的說明。
Steve Pacelli - SVP Corporate Affairs
Steve Pacelli - SVP Corporate Affairs
Thanks, Terry.
謝謝你,Terry。
Some of the statements that we will make in today's call may constitute forward-looking statements. These statements reflect management's expectations about future events, operating plans, and performance, and speak only as of the date hereof. These forward-looking statements involve a number of risks and uncertainties. A list of the factors that could cause actual results to be materially different from those expressed or implied by any of these forward-looking statements is detailed under Risk Factors and elsewhere in our annual report on Form 10-K, our quarterly reports on Form 10-Q, and our other reports filed with the SEC. We undertake no obligation to update publicly or revise these forward-looking statements for any reasons.
我們在今天電話會議中所做的部分陳述,可能構成前瞻性陳述。這些陳述反映管理層對未來事件、營運計畫與績效的預期,且僅截至本日有效。這些前瞻性陳述涉及多項風險與不確定性。可能導致實際結果與任何此等前瞻性陳述所明示或暗示者存在重大差異的因素清單,已在我們的 Form 10-K 年度報告、Form 10-Q 季度報告,以及其他向美國證券交易委員會(SEC)提交的報告中的「風險因素」及其他章節詳述。我們不承擔因任何原因公開更新或修訂這些前瞻性陳述的義務。
Terry?
Terry?
Terry Gregg - President and CEO
Terry Gregg - President and CEO
Thanks, Steve.
謝謝你,Steve。
On the agenda today, our customary order -- financial review by Jess. Then I'll go into the update for commercial and reimbursement and hospital partnership, insulin-pump partnership, development and regulatory update. Close it out with summary and conclusions and then we'll have a Q&A.
今天的議程依照我們慣例的順序——先由 Jess 進行財務回顧。接著我將更新商業化與給付(reimbursement)以及醫院合作夥伴關係、胰島素幫浦合作夥伴關係、研發與法規進度。最後以摘要與結論作結,然後進入問答。
Jess?
Jess?
Jess Roper - VP, CFO
Jess Roper - VP, CFO
Great. Thank you, Terry.
很好。謝謝你,Terry。
DexCom reported product revenues of $1.9 million for the second quarter of 2008, compared to $863,000 for the same quarter in 2007, an increase of 125%.
DexCom 2008 年第二季產品營收為 190 萬美元,較 2007 年同期的 86.3 萬美元增加 125%。
Sequentially, product revenue increased by 6% from the first quarter of 2008. During Q2, we sold approximately 1,050 Seven System starter kits.
以季對季來看,產品營收較 2008 年第一季成長 6%。第二季期間,我們約售出 1,050 套 Seven System 入門套組。
As of Q2 2008, we have upgraded approximately 1,600 first-generation three-day customers to our second-generation Seven product.
截至 2008 年第二季,我們已將約 1,600 位第一代三日型產品客戶升級至第二代 Seven 產品。
Sequentially, sensor revenues were up 15% from Q1.
以季對季來看,感測器營收較第一季成長 15%。
Total revenue for the second quarter of 2008 was $2 million and included a small amount of development grant revenue associated with our joint development agreement Animas Corporation entered into during Q1.
2008 年第二季總營收為 200 萬美元,其中包含少量與我們在第一季與 Animas Corporation 簽訂之共同開發協議相關的開發補助收入。
Cost of sales for the second quarter of 2008 totaled $3.4 million, compared to $2.9 million for the same quarter in 2007. The increase was primarily due to higher sales volume and approximately $250,000 in development cost of sales.
2008 年第二季銷貨成本合計 340 萬美元,較 2007 年同期的 290 萬美元增加。增加主要來自較高的銷售量,以及約 25 萬美元的開發銷貨成本。
The increase in product cost of sales relating to additional product sales was offset by lower direct labor costs and increased manufacturing absorption.
與額外產品銷售相關的產品銷貨成本增加,部分被較低的直接人工成本與較高的製造費用吸收所抵銷。
Our gross margin loss for the second quarter of 2008 was $1.4 million, compared to a loss of $2.0 million in 2007.
2008 年第二季毛利損失為 140 萬美元,較 2007 年的 200 萬美元損失改善。
Research and development expense increased by about $800,000 and totaled $4.8 million for the second quarter of 2008, compared to $4 million in the same quarter of 2007. Major elements of R&D expense included increased facilities costs, clinical trial costs and consulting fees. Sequentially, R&D costs remained flat from Q1.
研發費用增加約 80 萬美元,2008 年第二季合計 480 萬美元,較 2007 年同期的 400 萬美元增加。研發費用的主要項目包括設施成本、臨床試驗成本與顧問費用增加。以季對季來看,研發成本與第一季持平。
Selling, general and administrative expense totaled $7.2 million in Q2 of 2008, compared to $5.5 million in 2007. The increase was primarily due to increased sales and marketing costs. Major components of increased SG&A expense included approximately $550,000 in higher share-based compensation, $233,000 in increased trade show costs and $231,000 in additional sales commissions. Sequentially, SG&A expense increased by about $826,000 from Q1, due primarily to additional marketing and trade show-related costs.
2008 年第二季銷售、一般及行政費用(SG&A)合計 720 萬美元,較 2007 年的 550 萬美元增加。增加主要來自銷售與行銷成本上升。SG&A 增加的主要組成包括:約 55 萬美元較高的股份基礎給付、23.3 萬美元增加的展會成本,以及 23.1 萬美元新增的銷售佣金。以季對季來看,SG&A 較第一季增加約 82.6 萬美元,主要因額外的行銷與展會相關成本。
Net interest expense totaled $619,000 for the quarter, compared to net interest income of $204,000 for the same quarter in 2007. The increase in net interest expense was primarily due to lower average balances of our cash and marketable securities, combined with lower yields earned on those balances.
本季淨利息費用合計 61.9 萬美元,較 2007 年同期的淨利息收入 20.4 萬美元為高。淨利息費用增加主要由於我們現金與有價證券的平均餘額較低,加上這些餘額所取得的收益率下降。
Our net loss increased to $14.1 million for the second quarter of 2008, compared to $11.3 million during the same quarter in 2007. The net loss for the quarter included $2.8 million in non-cash expenses, centered primarily in share-based compensation.
2008 年第二季淨損擴大至 1,410 萬美元,較 2007 年同期的 1,130 萬美元增加。本季淨損包含 280 萬美元的非現金費用,主要為股份基礎給付。
During the quarter, we invested about $400,000 in capital equipment and facilities to support our business.
本季我們投資約 40 萬美元於資本設備與設施,以支援業務運作。
We ended the quarter with $43 million in cash, marketable securities, and restricted cash, and had working capital of $34 million.
本季期末我們持有現金、有價證券及受限制現金合計 4,300 萬美元,營運資金為 3,400 萬美元。
Cash and security balances decreased by $13.3 million during the quarter. The increased consumption of cash during the quarter, as compared to prior quarters, was primarily due to increased sales activity and marketing costs, additional inventory and payment towards annual insurance premiums.
本季現金與證券餘額減少 1,330 萬美元。相較前幾季,本季現金消耗增加主要由於銷售活動與行銷成本上升、存貨增加,以及支付年度保險費用。
In anticipation of moving all of our manufacturing operations to our new facility and to meet forecasted sales, we increased our inventory levels to about $2.8 million. This represented an increase of about $1 million from the prior quarter. We do not expect any significant increase in inventory in the near future.
為了因應將所有製造作業移轉至新廠房並滿足預測銷售,我們將存貨水位提高至約 280 萬美元,較前一季增加約 100 萬美元。我們預期短期內存貨不會再有顯著增加。
I would like to now turn it back to our President and CEO, Terry Gregg.
現在我想把時間交還給我們的總裁兼執行長 Terry Gregg。
Terry Gregg - President and CEO
Terry Gregg - President and CEO
Thanks, Jess.
謝謝你,Jess。
The second quarter of 2008 represented yet another quarter of sustained sequential growth for DexCom. As we look to the second half of 2008, we continue to see momentum building on the reimbursement front, and, more than ever, we believe broad-based reimbursement for CGM will be a key driver of increased sales going forward.
2008 年第二季對 DexCom 而言,是又一個連續季增長的季度。展望 2008 年下半年,我們持續看到在給付方面的動能正在累積,而且我們比以往任何時候都更相信,連續血糖監測(CGM)的廣泛給付將成為未來推動銷售成長的關鍵驅動因素。
We were extremely pleased to announce last week that we have entered into a contract with Blue Cross of California. This contract will enable us to process claims on behalf of qualified patients throughout much of the Anthem Blue Cross network, not just those patients residing in California.
我們非常高興在上週宣布,我們已與加州藍十字(Blue Cross of California)簽訂合約。此合約將使我們能代表符合資格的病患,在 Anthem Blue Cross 網路覆蓋的多數地區處理理賠申請,而不僅限於居住在加州的病患。
We were also pleased to learn in early July that Aetna has adopted a positive coverage decision for continuous glucose monitoring, and we are in the final stages of contract negotiation with Aetna.
我們也很高興在 7 月初得知 Aetna 已對連續血糖監測採取正向的給付決策,目前我們正處於與 Aetna 進行合約談判的最後階段。
While the coverage policies adopted to date are limited in scope, we believe these policies are an important first step to achieving broad-based coverage for CGM as a category, and while we're extremely excited about the progress we've made on the reimbursement front to ensure the long-term success of our business, we believe these initial coverage policies may actually present a short-term sales challenge.
雖然迄今採行的給付政策在適用範圍上仍有限,但我們相信這些政策是實現 CGM 作為一個品類獲得廣泛給付的重要第一步。儘管我們對在給付方面取得的進展感到非常振奮,並確信這將確保我們業務的長期成功,但我們也認為,這些初期的給付政策實際上可能在短期內對銷售造成挑戰。
To date, our CGM business has largely been a cash-pay model, with patients purchasing the Seven System and disposable sensors with their credit card, and any reimbursement received by these patients was largely on a one-off basis. Now we're faced with a situation where reimbursement is accelerating, and patients and physicians who are aware of this are becoming much more reluctant to initiate a cash purchase, knowing that reimbursement may be just around the corner. This is not atypical in medical device situations, where reimbursement is becoming more prevalent but is not universal yet. As more third-party payers issue coverage decisions, and DexCom enters into contracts with these payers, we expect this challenge will resolve itself.
截至目前,我們的 CGM 業務多以自費模式為主,病患以信用卡購買 Seven System 與一次性(拋棄式)感測器,而病患所獲得的任何給付多屬個案性質。如今我們面臨的情況是給付正在加速,知悉此情況的病患與醫師更不願意啟動自費購買,因為他們知道給付可能近在眼前。這在醫療器材領域並不罕見:給付逐漸普及但尚未全面。隨著更多第三方支付方發布給付決策,且 DexCom 與這些支付方簽訂合約,我們預期此一挑戰將自行化解。
In addition, we continue to caution that, even as payers adopt coverage policies and we enter into contracts, it will take time for patients and their physicians to learn about these coverage decisions, demonstrate medical necessity, and ultimately receive reimbursement for their CGM products.
此外,我們也持續提醒,即使支付方採行給付政策且我們完成簽約,病患與其醫師仍需要時間了解這些給付決策、證明醫療必要性,並最終取得其 CGM 產品的給付。
Nonetheless, the recent decision by Aetna reinforces our belief that other large payers will be forced to adopt coverage policies for continuous glucose monitoring or risk losing patients to competing insurance plans.
儘管如此,Aetna 最近的決策強化了我們的看法:其他大型支付方將被迫對連續血糖監測採行給付政策,否則將面臨病患轉向競爭保險方案的風險。
As we work to define our commercial strategy for the balance of 2008 and look out to 2009, we are pleased to announce the appointment of two new members of the executive team who will be joining us in September, both whom have worked for me previously.
在我們為 2008 年剩餘期間制定商業策略並展望 2009 年之際,我們很高興宣布任命兩位新的高階主管團隊成員,他們將於 9 月加入我們,且兩位都曾在過去為我工作。
Claudia Graham will join us as Vice President of Marketing, responsible for all aspects of DexCom's marketing effort. Claudia has extensive experience in the diabetes space. I initially hired Claudia in 1999 from Parke-Davis to lead our marketing effort as insulin pumps were gaining traction in adoption and reimbursement. She remained with Medtronic MiniMed post-acquisition and expanded her role to Vice President Global Therapy Access.
Claudia Graham 將加入我們擔任行銷副總裁,負責 DexCom 行銷工作的各個面向。Claudia 在糖尿病領域擁有豐富經驗。我在 1999 年自 Parke-Davis 延攬 Claudia,當時胰島素幫浦在採用與給付方面正逐步獲得動能,她負責領導我們的行銷工作。併購後她留任於 Medtronic MiniMed,並將其職責擴展至全球治療可近性副總裁(Vice President Global Therapy Access)。
On the international front, Peter Gerhardsson will join us as Vice President of International Business Development, where he will be responsible for the expansion of our business outside of the United States. Peter has spent 23 years in a number of global leadership positions with NovoNordisk. While I was at MiniMed, Peter ran our business in Scandinavia for five years before returning to Novo post-acquisition about three years ago.
在國際方面,Peter Gerhardsson 將加入我們,擔任國際業務發展副總裁,負責拓展我們在美國以外的業務。Peter 在 NovoNordisk 擔任多項全球領導職務長達 23 年。我在 MiniMed 任職期間,Peter 曾負責我們在斯堪地那維亞的業務五年,之後在約三年前收購完成後回到 Novo。
These two individuals are seasoned professionals with a significant presence in diabetes on a global basis. I feel very fortunate they are rejoining me to help lead DexCom as we expand our business across the globe.
這兩位人士都是資深專業人士,並在全球糖尿病領域具有重要影響力。我非常幸運他們再次與我共事,協助在我們將 DexCom 業務拓展至全球之際共同領導公司。
We also announced today the departure of Rod Kellogg, our Vice President of Sales, and note that on an interim basis, I will assume responsibility for the DexCom sales organization, and I expect to work closely with Claudia as we refine our messaging going forward.
我們今天也宣布銷售副總裁 Rod Kellogg 將離職,並說明在過渡期間,我將暫時負責 DexCom 的銷售組織;同時,我預期將與 Claudia 密切合作,持續精進我們未來的訊息傳達。
Our mission for the balance of 2008 is simple. We must continue to educate physicians and diabetes educators on the need to reduce glycemic variability in patients with the utilization of CGM. As I have stated previously, we are closely evaluating the size of our sales force and, as reimbursement expands, we will strategically address our sales coverage and adjust accordingly. We must refine our messaging further to educate patients on the benefits of continuous glucose monitoring. Shortly, we will be introducing a new patient-centric web portal and patient tutorial to assist patients in better understanding the value of CGM.
我們在 2008 年剩餘期間的使命很簡單。我們必須持續教育醫師與糖尿病衛教師,讓他們了解透過使用 CGM 來降低病患血糖變異性的必要性。如我先前所述,我們正密切評估銷售團隊規模,並將隨著給付範圍擴大,策略性地處理銷售覆蓋並相應調整。我們也必須進一步精進訊息傳達,以教育病患了解連續血糖監測的益處。不久之後,我們將推出以病患為中心的新網路入口網站與病患教學內容,協助病患更好地理解 CGM 的價值。
We must also continue to educate the private payer community on the role of CGM in assisting patients to better manage their glucose excursions, and we must work to obtain additional coverage decisions for CGM and enter into contracts with payers to reimburse our products.
我們也必須持續教育民間保險支付方社群,讓其了解 CGM 在協助病患更好管理血糖波動方面所扮演的角色;並且我們必須努力取得更多 CGM 的給付決策,並與支付方簽訂合約以對我們的產品進行給付。
We continue to see reimbursement as one of the key challenges to achieving widespread adoption of CGM. Although we are extremely pleased that several significant national payers have taken the lead in adopting positive coverage decisions, we reiterate that it will take time for this and other positive coverage decisions to filter down to patients and physicians and translate into sales, and it will take time for DexCom to secure contracts with these payers as coverage decisions are released.
我們仍然認為給付是實現 CGM 廣泛採用的關鍵挑戰之一。雖然我們對數家重要的全國性支付方率先採取正向給付決策感到非常欣慰,但我們再次強調,這些以及其他正向給付決策需要時間才能向下傳導至病患與醫師並轉化為銷售;同時,隨著給付決策陸續發布,DexCom 也需要時間與這些支付方完成合約簽訂。
I want to move on to the discussion on the in-hospital continuous glucose monitoring system. We continue to be extremely pleased with the rapid development of our in-hospital continuous glucose monitoring system. We recently completed yet another in-clinic human feasibility trial in which we were again able to demonstrate prospective accuracy that exceeded the ISO standard for therapeutic use.
我想接著討論院內連續血糖監測系統。我們對院內連續血糖監測系統的快速開發進展仍感到非常滿意。我們最近又完成了一項門診臨床的人體可行性試驗,在該試驗中,我們再次證明其前瞻性準確度超過了用於治療用途的 ISO 標準。
We continue to make significant advances in our membrane technologies that will allow us to block most common sources of drug-related interference in the critical care setting, including acetaminophen. We're on track to complete our development efforts for a first-generation product and commence a pivotal trial before the end of 2008. We believe this would enable us to commercialize our first product in the critical care setting by the end of 2009.
我們在膜技術方面持續取得重大進展,這將使我們能在重症照護環境中阻隔多數常見的藥物相關干擾來源,包括乙醯胺酚(acetaminophen)。我們正按計畫在 2008 年底前完成第一代產品的開發工作並啟動關鍵性試驗。我們相信這將使我們能在 2009 年底前於重症照護場域商業化我們的第一項產品。
We remain committed to commercializing our in-hospital product through an established partner with experience in the critical care marketing.
我們仍致力於透過在重症照護行銷方面具備經驗的既有合作夥伴,來商業化我們的院內產品。
In our last earnings call, I stated that we expected to complete technical and business due diligence and finalize negotiations with a chosen partner within a 90-day period. My primary motivation for this self-imposed deadline was to force potential partners, many of whom are very large organizations accustomed to operating at glacial speeds, to move more rapidly if they were serious about a deal with DexCom. My statement has had the desired effect. We're now in late-stage negotiations and expect to be in a position to announce a deal by the end of this quarter or early next quarter.
在上一次財報電話會議中,我表示我們預期在 90 天內完成技術與商務盡職調查,並與選定的合作夥伴完成談判。我為自己設定此期限的主要動機,是為了促使潛在合作夥伴(其中許多是習慣以極慢速度運作的大型組織)若真有意與 DexCom 交易,就必須加快腳步。我的發言已達到預期效果。我們目前已進入後期談判,並預期可在本季末或下季初宣布達成協議。
Moving on to our insulin-pump partnership update, we continue to make significant and substantial progress on the joint development of integrated insulin-pump CGM systems with both Animas Corporation and Insulet. Our continued goal is to complete all development, clinical and regulatory efforts with Animas and be positioned to launch our first product during the summer of 2009, but as you are well aware, the timing of the regulatory process is uncertain. We would expect the combined product with Insulet to follow later in 2009.
接著更新我們的胰島素幫浦合作進展:我們與 Animas Corporation 以及 Insulet 共同開發整合式胰島素幫浦 CGM 系統,持續取得重大且實質的進展。我們持續的目標是完成與 Animas 相關的所有開發、臨床與法規工作,並在 2009 年夏季推出我們的第一項產品;但如各位所知,法規審查流程的時程具有不確定性。我們預期與 Insulet 的組合產品將在 2009 年稍晚跟進。
In the interim, we continue to work on an informal basis with each of our insulin-pump partners to promote our respective products within our target markets.
在此期間,我們仍以非正式方式與各胰島素幫浦合作夥伴合作,在我們的目標市場中推廣彼此的產品。
We are also pleased to report that we have filed a PMA Supplement for a third-generation continuous glucose monitoring system with the Food and Drug Administration. Data from our approval support trial demonstrated significant improvements in system on time and improved accuracy, as compared to our current product. In addition, our third-generation system will include trend arrows to complement our trend graph, and entry capabilities, such as insulin intake, meals, exercise, as well as configurable alarms.
我們也很高興報告,我們已向美國食品藥物管理局(FDA)提交第三代連續血糖監測系統的 PMA 補充申請。我們的核准支持性試驗數據顯示,與現行產品相比,系統有效運作時間(on time)顯著提升且準確度更佳。此外,我們的第三代系統將加入趨勢箭頭以補強趨勢圖,並提供輸入功能,例如胰島素攝取、餐食、運動,以及可設定的警報。
Keeping in line with generational iterations, we continue to make progress on our fourth-generation product. We expect this design to incorporate an enhanced membrane system for even greater accuracy and be suited for large volume production.
依循世代迭代的節奏,我們在第四代產品上也持續取得進展。我們預期此設計將納入強化的膜系統以達到更高準確度,並適用於大批量生產。
Additionally, our fifth-generation sensor is now being tested in humans in connection with our in-hospital product.
此外,我們的第五代感測器目前正配合院內產品進行人體測試。
Finally, we continue to pursue a CE mark for the Seven. We are currently in the midst of our ISO audit and hope to be granted a CE Mark before the end of the year. This would enable us to begin conducting clinical trials in Europe later this year or very early next year.
最後,我們仍持續為 Seven 取得 CE 認證。我們目前正進行 ISO 稽核,並希望在年底前獲得 CE 認證。這將使我們能在今年稍晚或明年非常早的時候開始在歐洲進行臨床試驗。
In summary, I've now been on the job for 13 months, and as I look back over that period of time, I've seen a tremendous transformation in the attitudes of the key opinion leaders on the benefits of CGM. At the 2007 American Diabetes Association meeting, CGM was described from the podium as "interesting technology, probably for the most intensively-managed patients, with reimbursement at least two to three years away."
總結而言,我到任已 13 個月;回顧這段期間,我看到關鍵意見領袖對 CGM 益處的態度出現了巨大的轉變。在 2007 年美國糖尿病協會(ADA)會議上,CGM 在台上被形容為「有趣的技術,可能只適用於管理最密集的病患,而給付至少還要兩到三年才會到來。」
Fast-forward to today, and those same thought-leaders are now saying CGM will be the standard of care in the next two to three years for a broad segment of the diabetes population. They now understand that the value of reducing glycemic variability in patients on a daily basis is rapidly replacing the utilization of A1c as a measure of glucose control.
快轉到今天,同樣的思想領袖如今表示,在未來兩到三年內,CGM 將成為涵蓋廣大糖尿病族群的照護標準。他們現在理解,日常降低病患血糖變異性的價值,正迅速取代以 A1c 作為血糖控制衡量指標的做法。
And reimbursement is here and is rapidly gaining traction. We continue to create positive experiences for patients and health care professionals. Almost daily, I hear reports of patients achieving their best-ever glucose control without increasing their exposure to hypoglycemia.
而給付已經到來,且正迅速取得進展。我們持續為病患與醫療專業人員創造正向體驗。幾乎每天,我都會聽到病患在不增加低血糖暴露風險的情況下,達到有史以來最佳血糖控制的回報。
With our leadership role in CGM, we must stay the course in building the category so that we will ultimately gain acceptance of CGM as the best standard of care for diabetes management.
憑藉我們在 CGM 的領導地位,我們必須持續推動並建立此品類,最終讓 CGM 被接受為糖尿病管理的最佳照護標準。
Thank you. We'll now take questions.
謝謝。接下來我們開始提問。
Operator
Operator
Thank you. (OPERATOR INSTRUCTIONS.) And first, we'll go to Tom Gunderson with Piper Jaffray.
謝謝。(接線員指示。)首先我們請 Piper Jaffray 的 Tom Gunderson。
Tom Gunderson - Analyst
Tom Gunderson - Analyst
Hi. Good afternoon. Just a couple of quick checks here on what you said. You said inventory -- you didn't expect inventory to go up from here, but since you, I think, raised inventory to accommodate the move and give you a little safety stock, is it fair to assume that it might decrease in the second half, Terry?
嗨,午安。我這裡有幾個快速確認。你提到庫存——你不預期庫存會從這裡再上升,但因為你們(我想)提高了庫存以因應搬遷並提供一些安全庫存,所以是否可以合理推論下半年庫存可能會下降,Terry?
Terry Gregg - President and CEO
Terry Gregg - President and CEO
Well, that's the goal. We'd like to be in -- ultimately, Tom, to adjust in time kind of manufacturing environment. We're not there yet. Some of the other items that we had to go forward on are some of our longer-lead items, which we increased in terms of that inventory because we are not, at this point, given our run rate, able to take complete advantage of some of our longer-lead items. We had to buy those in advance bulk in order to get some price considerations, but also, we'll keep those and they translate into inventory. I don't expect, at this point, to have to rebuy some of those in the next quarter. We will adjust our inventory levels accordingly, but at this point, it was -- as we transition from one facility and bring everything in-house, I didn't want to run the risk of carrying -- of the jeopardy of going into a back quarter. So I would say we're not going to build it. We'd like to kind of bring it down a bit. But we're going to keep a watchful eye on it.
嗯,那是目標。Tom,最終我們希望能調整到即時製造(just-in-time)的環境。我們還沒到那一步。我們必須提前推進的一些其他項目,是部分交期較長的物料;由於以我們目前的運轉速率,現階段還無法充分利用某些長交期物料,因此我們在這些物料的庫存上做了增加。我們必須提前以較大量採購,除了取得一些價格上的考量之外,也會把這些物料保留下來,而它們就會反映為庫存。就目前而言,我不預期下個季度需要重新採購其中一些物料。我們會相應調整庫存水位,但在此時點——當我們從一個廠房過渡並把所有作業移回內部時,我不想冒著在某個季度出現缺貨的風險。所以我會說我們不會再把庫存堆高;我們希望能稍微降一些。但我們會密切留意。
Tom Gunderson - Analyst
Tom Gunderson - Analyst
Got it. Thanks for that. And then clarification on the sales and marketing management. You're going to be interim head of sales. Will that fall under Claudia's job description or do you still need a head of US sales?
了解,謝謝。接著釐清一下銷售與行銷管理方面:你將暫代銷售主管。這會納入 Claudia 的職務範圍之下嗎?還是你們仍需要一位美國銷售主管?
Terry Gregg - President and CEO
Terry Gregg - President and CEO
It does not fall under Claudia's description. What we -- I have three regional sales directors in the field now. Two of them have been with me in my former life as head of MiniMed. I want to truly understand what their needs are in order to be more successful. I think we've done an outstanding job of driving the push from the key opinion leaders, as evidenced by my summary comments. I think now it's part of why I want Claudia on board, in particular, and staffing up a bit more on the marketing side -- is to move that messaging to -- now what we need is the patient [pull] and she's excellent at delivering that message. She'd done it for me and for Medtronic MiniMed. I think from that standpoint, we'll continue to look at potential candidates, but I'm not in any rush to go out and hire somebody. I know this business quite well. These guys have -- two out of three have reported to me previously. And so I want to get a better feel with being in the street for a while before we make a decision to go in a different direction.
這不符合 Claudia 的描述。我們——我現在在第一線有三位區域銷售總監。其中兩位在我前一段職涯擔任 MiniMed 負責人時就跟著我。我想真正了解他們的需求是什麼,才能更成功。我認為我們在推動關鍵意見領袖(KOL)的帶動方面做得非常出色,這也從我總結性的評論中可見一斑。我想現在——這也是我特別希望 Claudia 加入、並在行銷端再多補一些人力的原因——是要把那個訊息推進到——我們現在需要的是病患端的[拉動],而她非常擅長傳遞那個訊息。她曾為我、也為 Medtronic MiniMed 做過。我想從這個角度來看,我們會持續留意潛在候選人,但我並不急著出去再聘一個人。我很了解這個產業。這些人——三位之中有兩位以前就向我彙報。所以在我們決定是否要走不同方向之前,我想先在市場第一線待一段時間,取得更好的感受。
Tom Gunderson - Analyst
Tom Gunderson - Analyst
Okay. And then last question will be a broader one and it ties into sort of the economy and the paying out of pocket. You mentioned sort of this switch to reimbursement and less of a willingness by some to pay out of pocket when they know reimbursement might be coming soon. I understand that. Have you gotten anything from the field that tells you that because the economy is tough out there -- because this can be considered sort of a medical consumer product in some ways -- that they're either using the sensor longer -- pushing the limits -- or using it only part of the month kind of thing? Any change simply because of the cost of it, or is it just pretty much steady as she goes from previous trends?
好的。那最後一個問題會比較宏觀一些,並且與經濟情勢以及自費支付有關。你提到某種程度上從自費轉向給付(reimbursement),以及當有些人知道給付可能很快就會到來時,他們自費的意願會降低。我理解這點。你從第一線有沒有得到任何回饋顯示,因為外部經濟很艱困——而且這在某些方面可被視為一種醫療消費性產品——所以他們要嘛把感測器用得更久、把使用極限往上推,或是每個月只用部分時間?是否因為成本而有任何改變,還是基本上就像以往趨勢一樣維持穩定?
Terry Gregg - President and CEO
Terry Gregg - President and CEO
No. I think, obviously, the economy is playing and having a bearing on some of this. Certainly, I will tell you that today, our sensors are the most reliable that they've ever been in the history of this company. That's both -- obviously, excellent news from the standpoint that our technology is the best that's on the market. The other side of that is they're using them longer. When we look at -- it's not uncommon now. We used to say seven to ten days. I'm saying probably the average is north of that. So we're not getting that reorder. We do -- and a large portion of the population, when we look at reorders -- we know they're using them 24/7 from that standpoint. Others are using them more episodically. We do have a decent business with physicians that have acquired the hardware -- the durable -- and they'll put patients on to test -- allow the patients to utilize the product for a couple of weeks. So we've got a number of different categories. But since it is, as you've described it, a bit elective, we do see a bit of that. We're asking patients, once they've acquired the durable piece, to spend -- in the case if they don't have reimbursement -- upwards of $2,000, and I think that they're looking at the economy and their durable spending, just like anybody else -- I think as we move more towards the reimbursement model, their resistance to that diminishes accordingly. But there are a significant group of people who, regardless of the economy, believe they've got to utilize the product 24/7, and that's -- that value proposition is something that, in terms of messaging, Tom, that there's a reason that they do that, and they have found great benefit that justifies their utilization. Obviously, we've got to message that more appropriately to the rest of the diabetes population.
沒有。我認為很顯然,經濟確實在其中發揮作用並對部分情況造成影響。當然,我可以告訴你,今天我們的感測器是公司歷史上最可靠的一代。這一方面——顯然——從我們技術是市場上最好的角度來看是非常好的消息。另一方面則是他們會用得更久。當我們觀察——現在這並不罕見。我們以前會說七到十天。我現在會說平均可能高於那個水準。所以我們沒有拿到那個再訂購(reorder)。我們確實——而且在我們看再訂購時,有相當大一部分族群——我們知道他們是以 24/7 的方式使用。其他人則比較是間歇性(episodic)使用。我們也有一塊不錯的業務來自醫師,他們已經取得硬體——耐用設備(durable)——然後會讓病患上機測試——讓病患使用產品幾週。所以我們有幾個不同的類別。但由於它如你所描述的,有點偏選擇性(elective),我們確實看到一些這樣的情況。我們要求病患在已經取得耐用設備之後——若沒有給付——要支出最高可達 2,000 美元以上;我想他們會看經濟狀況與他們在耐用品上的支出,就像其他人一樣——我想隨著我們更往給付模式移動,他們對此的抗拒也會相應降低。但也有一大群人不論經濟如何,都認為他們必須 24/7 使用產品;而那——那個價值主張在訊息傳遞上,Tom,他們之所以這麼做是有原因的,而且他們已經發現很大的效益,足以合理化他們的使用。顯然,我們必須把這個訊息更適切地傳遞給更廣泛的糖尿病族群。
Tom Gunderson - Analyst
Tom Gunderson - Analyst
Got it. Thank you.
了解。謝謝你。
Operator
Operator
And moving on, from Cowen, we'll go to Sara Michelmore.
接下來,從 Cowen 這邊,我們請 Sara Michelmore。
Sara Michelmore - Analyst
Sara Michelmore - Analyst
Yes. Thank you. Terry, you talked a little bit about sales and marketing staffing. Can you talk about, too, the organization that focuses on some of these reimbursement issues, whether it'd be folks involved in contracting or educating payers? Can you just describe the evolution there in terms of the staffing?
是的,謝謝。Terry,你稍微談到了一些銷售與行銷的人力配置。你也能談談專注於這些給付議題的組織嗎?例如參與合約簽訂或教育付款方(payers)的人員?你能否描述一下在人力配置方面的演進?
Terry Gregg - President and CEO
Terry Gregg - President and CEO
Sure. Let's look at it from the first part and that's the external group that reports to Steve Pacelli. They're still out in the field. They're staffed by three individuals who are all professionals in the managed care arena, and they continue to call on the third-party payer system. They're the ones that really get to the point of the contract, and then, of course, obviously, Steve's group internally -- the legal group we have here -- negotiate the terms of the contract. On the reimbursement side, that's one -- if you look at the increase in expenses on the sales side, we really flow that through, and we have had to increase the staffing on that, quite frankly -- on the reimbursement side. As we move to more contracting, we're going to have to continue to be sure that we have adequate staffing. We move that whole distribution cycle from -- as an example, from one of our DME suppliers. Once we have a contract in place, then these patients still have to undergo prior authorization, but that is done by us. So that means that paperwork comes in to us. The group inside has to process that paperwork back through the managed care provider, and once we then have prior authorization, we can ship product knowing that we'll get paid from the third-party payer in 45, 60-day kind of time frame. But that does require a back-office support system that we are building. None of that existed here. A year ago, none of it existed, so we are building that as part of the overall organizational structure as we move forward commercially.
當然。我們先從第一部分來看,也就是向 Steve Pacelli 彙報的外部團隊。他們仍在第一線,由三位人員組成,三位都是受託管理(managed care)領域的專業人士,並持續拜訪第三方付款方體系。他們是真正把事情推進到合約階段的人,然後當然——很明顯——Steve 的內部團隊——我們這裡的法務團隊——會去協商合約條款。在給付端,這是一個——如果你看銷售端費用的增加,我們確實把它反映在這裡;坦白說——在給付端——我們必須增加人力配置。隨著我們走向更多合約簽訂,我們必須持續確保人力配置充足。我們把整個配送循環從——舉例來說,從我們某一家 DME 供應商那裡——移轉過來。一旦合約到位,這些病患仍然必須經過事前授權(prior authorization),但那是由我們來做。這表示文件會送到我們這裡。內部團隊必須處理這些文件並回送給受託管理提供者;一旦我們取得事前授權,我們就可以出貨,並知道我們會在 45、60 天左右的時間框架內從第三方付款方收到款項。但這確實需要一套後勤支援系統(back-office support system),而我們正在建立。這裡以前完全沒有這些。一年前完全不存在,所以我們正在把它建起來,作為我們未來商業化推進時整體組織架構的一部分。
Sara Michelmore - Analyst
Sara Michelmore - Analyst
Okay. And in terms of the coverage policies, I guess, it does seem that a lot of these first-pass coverage policies are for infrequent, or perhaps intermittent, use of the devices, and I'm just wondering -- what do you think it's going to take to take those policies to the next level in terms of broader coverage and continuous use of these devices were initially conceived to be used?
好的。那就給付政策而言,我想,看起來很多這些第一輪的給付政策是針對不頻繁、或可能是間歇性使用這些裝置。我想問——你認為要把這些政策提升到下一個層級、在更廣泛的給付與連續使用(continuous use)方面——也就是這些裝置最初被設計用來使用的方式——需要什麼?
Terry Gregg - President and CEO
Terry Gregg - President and CEO
Well, I don't think they're intermittent, Sara. I would classify them -- they have specific policies for continuous use, and actually, if you were to talk about intermittent use, there's another whole diagnostic capability of these products that we could obviously explore with the physician population and, certainly, even in other diabetes-related -- gestational diabetes, as an example -- things that we have actually engaged in clinical trials on that I really haven't addressed during this call. But I -- is we look at the types of coverage -- it has comments like recurring hypoglycemia and things of that nature. I would say that, when we look at data points, our patients and every patient afflicted with diabetes have episodes of recurring hypoglycemia as established by the policies. So I think, although they -- those are the target because they're the most acute in terms of the implications -- you also notice that none of the coverage decisions have anything to do -- or any criteria related, at this point -- to A1c. So it's quite a broad policy. What we have to do is try to make the physicians understand. We've done well with the key opinion leaders. We now need to message down to that next tier or health care professional about the benefits of it. As far as the policy coverage, there's ample language to cover a very large portion of the diabetes population.
嗯,我不認為它們是間歇性的,Sara。我會把它們歸類為——它們有針對連續使用的特定政策;而且其實,如果你要談間歇性使用,這些產品還有另一整套診斷能力,我們顯然可以與醫師族群一起探索,當然也包括其他與糖尿病相關的——例如妊娠糖尿病(gestational diabetes)——我們其實已經在那方面進行臨床試驗,只是我在這通電話中還沒有談到。但我——當我們看給付類型——裡面有像是反覆性低血糖(recurring hypoglycemia)之類的描述。我會說,當我們看數據點時,我們的病患以及每一位受糖尿病影響的病患,都會出現政策所界定的反覆性低血糖發作。所以我認為,雖然他們——那些是目標族群,因為就影響而言最急迫——你也會注意到,目前所有給付決定都與——或任何條件目前都沒有——與 A1c 相關。所以這其實是一個相當廣泛的政策。我們必須做的是讓醫師理解。我們在關鍵意見領袖方面做得很好。現在我們需要把訊息往下傳遞到下一層級的醫療專業人員,讓他們了解其效益。至於政策給付,裡面有足夠的文字可以涵蓋非常大一部分的糖尿病族群。
Sara Michelmore - Analyst
Sara Michelmore - Analyst
Okay. And you talked a little bit about international business. Could you just remind us what your latest thoughts are and how you plan to develop that business? I assume that you're not conceiving of doing a large direct build-out, but if you could just give us a thought of where you're heading with that organization --
好的。你也稍微談到國際業務。你能否提醒我們你最新的想法,以及你打算如何發展那塊業務?我猜你並不打算進行大規模的直營擴編(direct build-out),但如果你能談談你對那個組織的發展方向——
Terry Gregg - President and CEO
Terry Gregg - President and CEO
Sure. I -- obviously, Peter has worked for me in the past. He ran our Scandinavian operations and is broad-based throughout Europe, Middle East and Africa -- was his domain for NovoNordisk. So what we intend to do -- right now, we're looking at it in two different ways. One, do something with a very large multinational company who already has the number of feet on the street, and those discussions are ongoing, and you can think of who they are in that world. Or secondly, we have been approached now -- I think the number is somewhere close to 100 different distributors throughout the world that have made inquiry about the opportunities to distribute our product in a wide domain. Obviously, we are in those discussions. There is a large meeting occurring next month in Rome -- The European Association for the Study of Diabetes. Peter and I and others are pretty much booked solid with a number of potential distributors, and also engaged with key physicians in each of those countries that already have some relationship with a distributor. They've made introductions. So we'll go about it one or the other way or a combination of both. But we are not going to hire a direct sales force.
當然。我——很明顯地,Peter 過去曾在我手下工作。他負責我們的斯堪地那維亞業務,並且在歐洲、中東與非洲都有廣泛的經驗——那是他在 NovoNordisk 的職責範圍。所以我們打算做的——目前我們從兩個不同的方向來看。第一,與一家已經擁有龐大跨國規模、且在當地已有大量業務人員(feet on the street)的公司合作;相關討論正在進行中,你也大概能想到在那個領域會是哪些公司。第二,我們目前也收到——我想數量接近 100 家——全球各地不同經銷商的接洽,他們詢問在廣泛區域內分銷我們產品的機會。很顯然,我們正在進行這些討論。下個月在羅馬將有一場大型會議——歐洲糖尿病研究協會(The European Association for the Study of Diabetes)。Peter、我以及其他同事的行程幾乎已被多家潛在經銷商排滿,同時也會與各國的關鍵醫師接觸;這些醫師往往已與某些經銷商有既有關係,並且已做了引介。因此我們會採取其中一種方式,或兩者結合。但我們不會聘用自建的直營銷售團隊。
Sara Michelmore - Analyst
Sara Michelmore - Analyst
Great. And it sounds like we could -- just some visibility on what you plan to do there by the end of the year (inaudible)?
很好。聽起來我們可以——只是想了解一下你們計畫在年底前要做什麼(聽不清)?
Terry Gregg - President and CEO
Terry Gregg - President and CEO
We're going -- it hinges on our successful migration through this ISO certification, and when we say we're literally in the middle of it -- it started yesterday. It is intended to end tomorrow.
我們會——這取決於我們能否順利完成這次 ISO 認證的遷移流程;而當我們說我們真的正在進行中——它是昨天開始的,預計明天結束。
Sara Michelmore - Analyst
Sara Michelmore - Analyst
Okay.
好的。
Terry Gregg - President and CEO
Terry Gregg - President and CEO
So assuming we pass that, then we would apply for CE mark. We would get that, hopefully, in the fourth quarter and begin putting in the mechanisms in place to -- which allows us then the market approval to go into the EU. Obviously, it's a -- we're looking at only a handful of countries in the EU that we believe reimbursement is such that would necessitate or be worthwhile for us to enter in the first year. So we're talking -- typically, those would be the UK, obviously. Germany, France, the Netherlands, possibly some of the Scandinavian countries.
所以假設我們通過了,那麼我們就會申請 CE 認證(CE mark)。我們希望能在第四季取得,並開始建立相關機制——使我們能取得進入歐盟市場的核准。很明顯,這——我們只鎖定歐盟中少數幾個國家,我們認為其給付(reimbursement)環境足以讓我們在第一年進入是必要或值得的。因此我們談的——通常會是英國,這是顯而易見的;德國、法國、荷蘭,可能還包括一些斯堪地那維亞國家。
Sara Michelmore - Analyst
Sara Michelmore - Analyst
Great. Thank you, Terry.
很好。謝謝你,Terry。
Operator
Operator
And moving on, we'll go to Mimi Pham with JMP Securities.
接下來我們請 JMP Securities 的 Mimi Pham。
Mimi Pham - Analyst
Mimi Pham - Analyst
Hi. Good afternoon. Regarding Abbott, are you seeing them in the top diabetes centers that you're in during the second quarter, and do you get a sense that they're helping you develop the US market and convert additional thought-leaders to CGM?
嗨,午安。關於 Abbott,你們在第二季所進入的頂尖糖尿病中心裡有看到他們嗎?你是否覺得他們正在協助你們開發美國市場,並讓更多意見領袖轉向使用 CGM?
Terry Gregg - President and CEO
Terry Gregg - President and CEO
Mimi, they have not had much of a presence. They have no sales force. They're using Smith's to distribute the product and some of the traditional DME suppliers. But we have not seen as active an effort on their part. When I talk to physicians, it's very spotty as to their availability of product, and so I think they've done some target introduction, but hopefully, as they gear up --. It's always -- as I have always cautioned everyone, going from an R&D environment to a production environment is never linear, and I think that most companies stumble a little bit when they move from R&D to a production, so they want to limit their exposure. I think the other -- and I can't speak for Abbott, but (inaudible) to say that product was originally attempted to be filed with the FDA in -- back in 2003. They probably need some upgrade to their product in order to be more competitive with the two products that are currently on the market.
Mimi,他們的能見度並不高。他們沒有銷售團隊。他們是透過 Smith's 來分銷產品,以及一些傳統的 DME 供應商。但我們沒有看到他們投入很積極的推廣。當我和醫師談時,產品供應的可得性非常零星,所以我認為他們做了一些目標式導入,但希望他們在加速布局之後——。一如我一直提醒大家的,從研發(R&D)環境轉到量產環境從來不是線性的;我認為多數公司在從研發走向量產時都會有些踉蹌,因此他們會想限制曝險。我想另外一點——我不能代表 Abbott 發言,但(聽不清)可以說,該產品最早曾嘗試在——早在 2003 年就向 FDA 申報。他們可能需要對產品做一些升級,才能在競爭上更接近目前市場上的兩款產品。
Mimi Pham - Analyst
Mimi Pham - Analyst
And then you talked about the current coverage decisions being somewhat limited in scope, but can you give us your estimate of what percent of the type 1 diabetics in the US -- you feel that they fit that -- the current coverage criteria?
另外你提到目前的給付核定(coverage decisions)在範圍上似乎有些限制,但你能否估計一下,在美國第一型糖尿病患者中——你認為有多少百分比符合目前的給付條件?
Terry Gregg - President and CEO
Terry Gregg - President and CEO
Well, I would tell you that, based on the data that I have seen on a wide variety of clinical trials, north of 95%. And if you look at how many patients go below 70 on a daily basis -- probably most patients. How many go above 250? Most patients. So it's a wide [continuing]. The problem with A1c, as an example, as a surrogate marker -- patients will attempt to do their best efforts to get below 7 because that's what ADA has established as the goal, and then they get there and they're still running 40 to 400. So unfortunately, as they try to drive their A1c down to an acceptable level, they also increase the risk of hypoglycemia because the band just moves down, and so I would say that an overwhelming majority of patients would qualify under the conditions set forth by these "coverage decisions" by the national payers.
嗯,我會告訴你,根據我看過的各式各樣臨床試驗數據,超過 95%。而且如果你看每天血糖低於 70 的患者有多少——大概是大多數患者。血糖高於 250 的有多少?也是大多數患者。所以這是一個很廣的範圍 [continuing]。以 A1c 為例,作為替代指標(surrogate marker)有個問題——患者會盡最大努力把 A1c 壓到 7 以下,因為那是 ADA 設定的目標;但他們達到之後,血糖仍可能在 40 到 400 之間波動。所以不幸的是,當他們試圖把 A1c 壓到可接受水準時,也會提高低血糖風險,因為整個區間只是往下移動。因此我會說,絕大多數患者都會符合這些全國性支付方所提出的「給付核定」條件。
Mimi Pham - Analyst
Mimi Pham - Analyst
Okay. I'm sorry. I thought you thought it was limited, but it sounds like (inaudible).
好的。抱歉。我以為你覺得它是有限的,但聽起來(聽不清)。
Terry Gregg - President and CEO
Terry Gregg - President and CEO
I don't think it's limited at all. I think it's just the opposite. I'm very comfortable with the coverage decisions that have been issued. I think they're great. They're actually more expansive than I would have estimated and predicted earlier when I said I thought the first one --first coverage decision would come in Q4 '08, and I had said back even in January that I thought it would be very limited and, in fact, they're much more expansive than I thought.
我不認為它有限,反而正好相反。我對已發布的給付核定非常放心。我覺得它們很棒。其實它們比我先前估計與預測的還要更具擴張性;我之前說我認為第一個——第一個給付核定會在 2008 年第四季出來,而我早在一月就說我覺得會非常有限;事實上,它們比我想的要寬鬆得多。
Mimi Pham - Analyst
Mimi Pham - Analyst
And then the last question. The 3-day STS users that haven't yet upgraded to the Seven -- have you actually gone back to each of them to see if they're interested in the Seven? And then is there something where, as you get more national coverage, you have their contact information and you can go back directly to them and see if they're interested in buying the Seven?
最後一個問題。那些使用 3-day STS、但還沒有升級到 Seven 的使用者——你們是否真的逐一回頭聯繫,確認他們是否對 Seven 有興趣?另外,當你們取得更多全國性給付後,你們是否有他們的聯絡資訊,可以直接回頭找他們,看看他們是否有興趣購買 Seven?
Terry Gregg - President and CEO
Terry Gregg - President and CEO
We reached out to them to the extent that we provided some upgrade opportunities for them. I would say, at this point, if they haven't upgraded, we are -- they've either lost interest potentially, they've migrated to possibly Medtronic with a pump, or that they're now, at this point -- we always have the opportunity to go back to them. I think, given where we're at right now, we need to focus more on new patients than the remaining patients who are former STS-3 patients.
我們在一定程度上有主動聯繫他們,並提供一些升級方案。我會說,到目前為止,如果他們還沒有升級,我們——他們可能已經失去興趣、可能轉去使用 Medtronic 的幫浦,或是他們現在——我們一直都有機會再回頭找他們。我認為以我們目前的狀況,我們需要把重心放在新病患,而不是剩下那些過去的 STS-3 病患。
Mimi Pham - Analyst
Mimi Pham - Analyst
Okay. Thank you very much.
好的。非常感謝。
Operator
Operator
And moving on, we'll go to Bill Plovanic with Canaccord Adams.
接下來我們請 Canaccord Adams 的 Bill Plovanic。
Bill Plovanic - Analyst
Bill Plovanic - Analyst
Great. Thank you. Good evening.
很好,謝謝。晚安。
Terry Gregg - President and CEO
Terry Gregg - President and CEO
Did you change your name, Bill?
Bill,你改名字了嗎?
Bill Plovanic - Analyst
Bill Plovanic - Analyst
It's close enough.
差不多啦。
Terry Gregg - President and CEO
Terry Gregg - President and CEO
Okay.
好的。
Bill Plovanic - Analyst
Bill Plovanic - Analyst
Just in terms of coverage, you've gotten a lot of coverage thus far, much faster than expected. Are there any major payers or any surprises you could see in the back half of this year? I know that you've been saying that, I think, by the end of next year kind of everything will be in place, but where do you kind of think we'll be at the end of this year and maybe mid-next year -- just any milestones or other major payers coming?
就給付覆蓋而言,你們目前已取得很多覆蓋,而且速度比預期快得多。今年下半年是否還有任何主要支付方,或你認為可能出現的意外情況?我知道你們一直說,我想是到明年年底左右一切都會到位;但你覺得今年年底以及明年年中大概會到什麼程度——是否有任何里程碑或其他主要支付方會加入?
Terry Gregg - President and CEO
Terry Gregg - President and CEO
Yes. We know we're undergoing tech assessment by a couple of the national payers. Assuming that gets through the process, I would expect at least one more this year. That is, within the last five months of the year. I could be surprised. Listen, I don't have the right crystal ball. I -- and earlier this year, I said first one in Q4. We've got two now, so --. I think everything is just happening a bit faster than we predicted because I think the -- number one, the number of claims being processed has increased dramatically at those payers. I think if those payers have also had to go to external review -- if they're spending money for those external reviews and they've lost a lot more of those reviews than they've ever won, that that's causing them to take a second thought. So I think you could probably see another one before the end of the year.
是的。我們知道有幾家全國性支付方正在對我們進行技術評估(tech assessment)。假設流程順利通過,我預期今年至少還會再有一家。也就是在今年剩下的五個月內。我也可能會感到驚訝。聽著,我沒有水晶球。我——而且今年稍早我說第一家會在第四季;現在我們已經有兩家了,所以——。我認為一切只是比我們預測的快一些,因為我想——第一,這些支付方處理的理賠申請(claims)數量大幅增加。第二,我想如果這些支付方也不得不進行外部審查——如果他們花錢做外部審查,且在那些審查中輸掉的比例遠高於以往贏的比例,那會促使他們重新思考。所以我認為你們很可能在年底前再看到一家。
Bill Plovanic - Analyst
Bill Plovanic - Analyst
Okay. And then any thoughts on the JDRF data that it's either going to be coming out at the AADE this week or it'll be at the EASD in Rome. Just any thoughts you may have on that.
好的。另外,對於 JDRF 的數據——可能會在本週的 AADE 公布,或是在羅馬的 EASD 公布——你對此有什麼看法嗎?
Terry Gregg - President and CEO
Terry Gregg - President and CEO
Yes. I'm pretty sure -- I'm sure the first time you're going to hear it from the podium is going to be EASD. I don't hear anything from JDRF at this point that there'll be any early announcements at AADE this week, and I -- they are very tight-lipped about the results. I've talked to some of the trial investigators and they're not even giving me a wink or a nod as to yea or nay, so --. We do know that, in terms of looking at time spent and target zone, that's -- they are very happy with that. That's a secondary endpoint, though, and we don't have any optics on the primary endpoint. [Other than that], it's an interesting development, though, because the more we talk about A1c, the less universally-accepted it is. In fact, we're going through now an issue with the scientists who don't want to use A1c at all. They want to now use glucose exposure and trying to come up with yet a new number. So I don't know how that's all going to tease out in terms of utilization of A1c anyhow. So I think it's more -- for us, it's a lot more important. And I think you're seeing the coverage decisions that are being made today by the reduction of time spent in hyper- and hypoglycemia and more time spent in utilization their target zone. (Inaudible.)
是的。我很確定——我確定你第一次會從講台上聽到的會是在 EASD。我目前沒有從 JDRF 那邊聽到任何消息說本週在 AADE 會有任何提前公告,而且——他們對結果守口如瓶。我跟一些試驗研究者談過,他們甚至連肯定或否定都不給我任何暗示,所以——。我們確實知道,就「花費時間」以及「目標區間」來看,他們——對此非常滿意。不過那是次要終點,而我們對主要終點仍然毫無掌握。[除此之外],這仍是個有趣的發展,因為我們越談 A1c,它就越不被普遍接受。事實上,我們現在正面臨一些科學家根本不想用 A1c 的問題。他們想改用葡萄糖暴露量,並試圖再提出一個新的數字。所以我也不知道,這在 A1c 的使用上最終會如何發展。因此我認為這更——對我們而言,重要得多。而且我想你也看到,今天所做出的給付覆蓋決策,是基於減少高血糖與低血糖的時間、以及更多時間維持在目標區間。(聽不清。)
Bill Plovanic - Analyst
Bill Plovanic - Analyst
Okay. I'm sorry. And then last, just -- you talk about the gen-four being more manufacturable. Does that mean that you would expect gross margins on that product north of 75%, or is that how you get to a 75% gross margin at scale?
好的。不好意思。最後一個——你提到第四代更容易製造。這是否表示你預期那個產品的毛利率會高於 75%,還是說你是透過這樣在規模化時達到 75% 的毛利率?
Terry Gregg - President and CEO
Terry Gregg - President and CEO
That is certainly how we get to robust gross margins. I don't want to put an absolute number on it because we're not there yet, but looking at what we have predicted, the folks we've got -- that we brought over, actually, from the bio-side organization now running our manufacturing environment --. Certainly, we have got to move to that type of manufacturing in order to achieve those kinds of gross margins. And this is the way we're going now. As I mentioned earlier, we have never seen such reliable product as we have right now, and the result -- why is that? That's because we're going through these manufacturing upgrades as we speak in anticipation. It never happens overnight. We always do it in -- sequentially, and that's what we're experiencing, so anytime we can get higher reliability, it directly translates back into our COGS and the whole process. So that's the goal.
那當然是我們達成強勁毛利率的方式。我不想給出一個絕對數字,因為我們還沒到那一步,但從我們的預測來看,我們引進的那些人——其實是從生物端組織調過來、現在負責我們製造環境的人——。毫無疑問,我們必須轉向那種製造方式,才能達到那樣的毛利率。而這就是我們現在前進的方向。如我先前提到的,我們從未見過像現在這樣可靠的產品,而結果——為什麼會這樣?那是因為我們正在進行這些製造升級,以因應未來需求。這不可能一夜之間完成。我們一向是——循序漸進地做,而這正是我們正在經歷的。因此,只要我們能提高可靠性,就會直接反映到我們的 COGS(銷貨成本)以及整個流程上。所以這就是目標。
Operator
Operator
And moving on, from Steve Ogilvie with ThinkPanmure.
接下來,請 ThinkPanmure 的 Steve Ogilvie 發問。
Steve Ogilvie - Analyst
Steve Ogilvie - Analyst
Hi, guys. Just a couple questions. First, just kind of wondering if the JDRF data isn't as we hope -- as you hope -- what DexCom's response will be, if there's some sort of a contingency plan? And then the second question would be if you could talk about headcount and how that's changed in the 13 months since you've been in charge and, looking forward -- if you see any major dynamics just there?
嗨,各位。兩個問題。第一個,我想了解如果 JDRF 的數據不如我們——不如你們所希望的——DexCom 會如何回應?是否有某種備案?第二個問題是,能否談談人員編制(headcount),在你上任的 13 個月以來有何變化,以及往前看——你是否看到那方面有任何重大動態?
Terry Gregg - President and CEO
Terry Gregg - President and CEO
Well, contingency with regards to JDRF -- no, I think that the --. If you look at the world of publication -- not only from us but from MiniMed, from Abbott -- there's overwhelming data to suggest the improvement in glucose control as a result from time spent improvement in target zone from hypoglycemia and hyperglycemia. I would be surprised if the outcome of the JDRF trial didn't reinforce that there are dozens of studies that have already demonstrated that. I think the real question on the JDRF trial that has been bantered about is will they reach the primary endpoint of a 0.5 reduction in A1c. And we have the history, so to speak, of the Star 1 trial from MiniMed in which, globally, they did not reach the primary endpoint, but I think if you really tease that data and look at patients that actually complied and used the product, it was significantly positive. If you look at the Star 2 trial, which was a precursor to their Star 3 trial, again demonstrating, with proper patient selection and representative use -- the Star 2 trial for MiniMed was also significantly positive, and we don't have the results from the Star 3 trial yet. So I don't know what the outcome will be looking at A1c, but even if they don't meet primary endpoint, I'm not sure that matters anymore. They didn't have -- when the JDRF trial was designed, we still thought A1c was the gold standard and it was something -- because we didn't have any other standard. With the advent of CGM, we now find that A1c is a terrible surrogate marker. So I'm not sure how valid it is. We are participating in a number of drug trials with our sensor that is still using A1c as a criteria, because that's what FDA utilizes for effectiveness, but these folks want sensor data to demonstrate reduction in glycemic variability because they believe that, regardless of what the outcome is on A1c, if they show reduction in glycemic variability, that's going to be more powerful than reduction in A1c because of its lack of consistency.
嗯,關於 JDRF 的備案——沒有,我認為——。如果你看已發表的文獻世界——不只是我們,還有 MiniMed、Abbott——有壓倒性的數據顯示,透過改善在目標區間內的時間、減少低血糖與高血糖的時間,能夠改善葡萄糖控制。我會很驚訝如果 JDRF 試驗的結果沒有強化這一點,因為已經有數十項研究證明了。大家一直在討論的 JDRF 試驗真正問題是:他們是否能達到主要終點,也就是 A1c 降低 0.5。就某種意義上,我們有 MiniMed 的 Star 1 試驗歷史:在全球範圍內,他們沒有達到主要終點,但我認為如果你仔細拆解數據、看那些真正遵從並使用產品的患者,結果是顯著正向的。再看 Star 2 試驗——那是他們 Star 3 試驗的前導——同樣顯示在適當的患者選擇與具代表性的使用下——MiniMed 的 Star 2 試驗也是顯著正向,而我們還沒有 Star 3 試驗的結果。所以我不知道就 A1c 而言結果會如何,但即使他們沒有達到主要終點,我也不確定這是否還重要。當 JDRF 試驗設計時,我們仍認為 A1c 是黃金標準,且它是某種——因為我們沒有其他標準。隨著 CGM 的出現,我們現在發現 A1c 是一個很糟的替代指標(surrogate marker)。所以我不確定它有多有效。我們正以我們的感測器參與多項藥物試驗,仍以 A1c 作為標準之一,因為 FDA 用它來衡量有效性,但這些人希望用感測器數據來證明血糖變異度降低,因為他們相信,不論 A1c 的結果如何,只要顯示血糖變異度降低,因為 A1c 缺乏一致性,這會比 A1c 降低更有說服力。
Steve Ogilvie - Analyst
Steve Ogilvie - Analyst
And if I could just follow up real quick. Do you think CMS will be able to look beyond A1c like you're speaking of?
我再快速追問一下。你認為 CMS 能夠像你所說的那樣,不只看 A1c 嗎?
Terry Gregg - President and CEO
Terry Gregg - President and CEO
Yes, I think so. We have to do that trial. That's an age-related population that we haven't. What is interesting and -- CMS issued a decision with respect to they won't pay for two hospitals for lack of good glucose control because they recognize that glucose control is important. And that's been a recent decision on their part, and we need to understand that better as what it relates to us, but it certainly is obvious from the -- on a global perspective that CMS understands that, number one, the value of the glucose control in that setting -- in the in-hospital setting, which is important, and what it means to encourage the hospital sectors to pay more close attention to that, which bodes well in terms of the efforts that we've got in the hospital sector.
是的,我想可以。我們必須做那個試驗。那是我們尚未涵蓋的年齡相關族群。有趣的是——CMS 最近做出一項決定:由於缺乏良好的血糖控制,他們不會為兩家醫院支付費用,因為他們認知到血糖控制很重要。那是他們近期的決策,我們需要更深入理解這與我們的關聯,但從全球角度來看,很明顯 CMS 理解:第一,在那個情境——住院情境——血糖控制的價值,這很重要;以及這對於鼓勵醫院端更密切關注血糖控制意味著什麼,這對我們在醫院領域所做的努力而言是個好兆頭。
Steve Ogilvie - Analyst
Steve Ogilvie - Analyst
I'm sorry. And then just quickly on headcount. Thanks.
不好意思。那再快速問一下人員編制。謝謝。
Terry Gregg - President and CEO
Terry Gregg - President and CEO
Yes. We've -- the bulk of the headcount increase, quite frankly, is in temporary -- on the manufacturing side. So we're gauging that. We really haven't had a tremendous increase in terms of the total number of bodies. I think we've been selective where we had deficiencies, Steve. We've improved and upped, in some cases, but particularly in the engineering group, I would say we've added some bodies and also in terms of the quality group. As we have moved to ISO standards as an organization, we've had to implement better quality systems and that didn't exist before I got here, and so once we've got it to the point where we believe we can pass an ISO certification, we've got to have sustainability of those processes and validations. So that would be the primary area. The other area I expect to -- I want to add in the marketing area one or two more bodies than we have today, which, today, we have one. So I think that's from that staffing standpoint. But we're pretty well set other than that. Again, I want to look at the sales force, that we get greater reimbursement coverage. Right now, we do not have a tremendous geographical coverage. We are expanding beyond the hundred key target clients, but that's not enough. We're leveraging the relationships with both Animas and Insulet, and they -- Animas has got 200 people in the field and Insulet 100. But that's in a pump world and we still think MDI is extremely important to us. So as we need, we'll try to leverage where we can, but if it justifies expansion -- not a huge number -- but we will begin -- we're looking at each of the territories and what they're doing and are they able to do more.
是的。我們——坦白說,人員增加的大部分是在製造端的臨時人力。所以我們正在衡量這點。就總人數而言,我們其實沒有大幅增加。我想我們在有不足之處採取了選擇性補強,Steve。我們在某些方面有所改善並增加人力,但特別是在工程團隊,我會說我們增加了一些人手,另外在品質團隊也是。隨著我們作為一個組織轉向 ISO 標準,我們必須導入更好的品質系統,而在我來之前這些並不存在;因此當我們把它做到我們相信能通過 ISO 認證的程度後,我們還必須讓這些流程與驗證能夠持續運作。所以那會是主要領域。另一個我預期——我想在行銷領域再增加一到兩個人手;而目前我們只有一個。所以在人力配置上大概是這樣。除此之外我們基本上已經就緒。再者,我想檢視銷售團隊,以便取得更高的給付覆蓋。現在我們的地理覆蓋並不廣。我們正在擴展到一百個關鍵目標客戶之外,但那還不夠。我們正在利用與 Animas 和 Insulet 的合作關係——Animas 在外勤有 200 人,Insulet 有 100 人。但那是在幫浦領域,而我們仍認為 MDI(多次每日注射)對我們極其重要。因此在需要時,我們會盡量利用可利用的資源,但如果擴張有其正當性——不會是很大的數量——我們就會開始——我們正在檢視每個區域的狀況與他們在做什麼,以及他們是否能做得更多。
Operator
Operator
And our final question will come from (inaudible) with Sanders Morris Harris.
我們最後一個問題將來自 Sanders Morris Harris 的(聽不清)。
Unidentified Participant
Unidentified Participant
Hi, guys. It's [Raj]. Terry, just given that -- pardon me. I jumped a little late on the call, so if you have answered this, my apologies. But just given the macroeconomic environment, and if we are doing the math right, given the cash burn and the current securities available for sale on the balance sheet, can you just help us with what kind of exposure do you all have for those securities? And also, as a subset of that question, how do you look upon a potential cash, raise given this environment, two quarters down the line?
嗨,各位。我是 [Raj]。Terry,基於——不好意思。我稍微晚了一點才加入電話會議,所以如果你已經回答過這個問題,先跟你致歉。但就目前的總體經濟環境來看,如果我們的計算沒錯,考量現金消耗以及資產負債表上目前可供出售的證券,你能否協助我們了解你們在這些證券上的曝險大概是什麼程度?另外,作為這個問題的延伸,在這樣的環境下,你們如何看待在接下來兩個季度之後可能進行的現金募資?
Terry Gregg - President and CEO
Terry Gregg - President and CEO
Well, I'm going to ask Jess to talk about the exposure on the securities which, I think -- we have always been ultraconservative from that standpoint, but -- and I can't comment, obviously, on any financing situations. We review that with the board on a -- literally a monthly basis. I would just say this. In the discussions that we have previously had with the hospital sector, that will -- and the discussions we're having now in terms of the -- I would say we are in very late-stage negotiations. There is an upfront payment for exclusivity in that, which will impact us in a positive way from a cash infusion. Secondarily, the conditions -- there are R&D-related payments that, when you look at the expenses that, in the second quarter -- and even in the first quarter -- we're spending more on the R&D side, quite frankly, in the hospital sector as we push to get that product into a position in order to negotiate a definitive contract. I -- so -- in both of those, I think there's some mitigation of that and I'm looking to Jess. Anything else on the cash securities? They're very safe. We don't do anything in a risky -- on our -- the securities that we use (inaudible).
嗯,我會請 Jess 談談證券曝險。我想——從那個角度來看,我們一向都非常保守,但——而且我顯然不能評論任何融資情況。我們會在——幾乎是每月一次——與董事會檢視這件事。我只想說:在我們先前與醫院端所進行的討論中,那將——以及我們目前就——我會說我們已經進入非常後期的談判階段。當中有一筆為取得排他性而支付的預付款,這將以正面的方式影響我們,帶來現金注入。其次,條件方面——有一些與研發相關的付款;當你看第二季——甚至第一季——的費用時,坦白說,隨著我們推動醫院端產品達到可談判最終合約的狀態,我們在醫院端的研發支出確實更高。我——所以——在這兩方面,我認為都有一些緩解作用,我也想聽聽 Jess 的看法。現金與證券方面還有其他補充嗎?它們非常安全。我們不會做任何高風險的——就我們——所使用的證券而言(聽不清)。
Jess Roper - VP, CFO
Jess Roper - VP, CFO
Yes. That's right. Just to clarify. We have a very short-term portfolio, and our philosophy is to preserve our cash and capital, not to try to maximize our yields on those. We haven't had any downgrades in securities, and we don't hold any auction-rate securities or have any exposure on that side.
是的,沒錯。補充說明一下:我們的投資組合期限非常短,我們的理念是保全現金與資本,而不是試圖把這些投資的收益率最大化。我們持有的證券沒有遭到任何降評,我們也不持有任何拍賣利率證券(auction-rate securities),在那方面也沒有任何曝險。
Unidentified Participant
Unidentified Participant
Okay. Fair enough. And Terry, on the JDRF trial, given that there are multiple CGM systems used -- Freestyle, DexCom, the Medtronic system -- how do you look upon the data as an aggregate when you use different systems with different specificities, sensitivities? And let's say you get a certain aggregate data set. Is there a subset analysis plan specifically related to the DexCom data? Because the overall might -- may or may not give you a positive picture, and then everyone is going to be slicing and dicing the data and looking separately. So how would you -- what's the thought process in terms of looking at data specifically for DexCom, or is that even planned at all?
好的,明白了。Terry,關於 JDRF 試驗,鑑於使用了多種 CGM 系統——Freestyle、DexCom、Medtronic 系統——當你使用不同系統、且各自的特異性與敏感度不同時,你如何看待彙總後的整體數據?假設你得到一組彙總數據集,是否有針對 DexCom 數據的子集分析計畫?因為整體結果可能——也可能不會——呈現正面圖像,然後大家都會把數據切來切去、分別看。那你會如何——在針對 DexCom 的特定數據進行解讀方面,你們的思考流程是什麼?或者根本沒有這樣的規劃?
Terry Gregg - President and CEO
Terry Gregg - President and CEO
Well, it's -- let me put it this way. We have asked for that data to be segregated out at the time when they have concluded with it so that we can do exactly as you're suggesting. We don't own that trial. All we did was provide product, as did MiniMed and Abbott, so we don't have the authority under the contractual relationship with JDRF to demand that. Again, we have asked, I think, in an air of cooperation, hopefully that they will grant us that request, as I'm sure MiniMed and Abbott would like as well, because there are -- as you've stated, there's a big delta between the different technologies, and obviously, if there were some reason the other two systems weren't performing as well as ours, we would want to be able to stand on our own. Obviously, we're at 7 days and the others are at less frequent. One of the things that we're doing -- one of the attributes that we have that we've agreed with JDRF -- we have the ability to look at on-time -- the time the patients actually look at their receiver screen, and the other companies don't have that ability. So as hopefully a quid pro quo type of -- we will give that information to JDRF through our download software. So I'm hoping that we'll be able to analyze that appropriately. But no guarantees.
嗯——我這樣說吧。我們已經要求在他們完成試驗後,將數據分開整理,讓我們能夠如你所建議的那樣進行分析。我們並不擁有那個試驗。我們所做的只是提供產品,MiniMed 和 Abbott 也同樣提供產品,因此在與 JDRF 的合約關係下,我們沒有權力要求他們一定要這麼做。再說一次,我們已經提出要求,我想是在合作的氛圍下,希望他們能同意我們的請求;我相信 MiniMed 和 Abbott 也會希望如此,因為——如你所說——不同技術之間差異很大,而顯然,如果另外兩套系統因某些原因表現不如我們,我們會希望能夠以我們自身的表現來說話。很明顯,我們是 7 天使用期,而其他的是更短的使用頻率。我們正在做的一件事——也是我們與 JDRF 同意的一項特性——是我們有能力查看「即時」——也就是病患實際查看接收器螢幕的時間,而其他公司沒有這個能力。因此,作為一種 quid pro quo(互惠交換)——我們會透過我們的下載軟體把這些資訊提供給 JDRF。所以我希望我們能夠適當地分析這些資料。但不保證。
Unidentified Participant
Unidentified Participant
And finally, how would you quantify -- or maybe you have already mentioned this. How would you quantify your relationship with Insulet and Animas, specifically related to this quarter and what you see in the next two quarters?
最後,你會如何量化——或者你可能已經提過——你們與 Insulet 和 Animas 的合作關係,特別是就本季度以及你對接下來兩個季度的看法?
Terry Gregg - President and CEO
Terry Gregg - President and CEO
Well, I -- in both of them, I only have high regard, and my comments on both companies are tremendous. I know, in particular, the good folks at Animas we meet with weekly, either in person or telephonically. The teams are highly-integrated in driving this product forward. They've got a lot more resources to bear on this than the Insulet folks, but again, we're actively engaged with Insulet as well. They had, obviously -- as they moved to utilize the OmniPod for a fertility drug with Ferring Labs, they were concentrated in that particular endeavor and filed a separate 510(k) for that, so I think there was a little bit of resource allocation. But we are actively talking to them as well. We talked to JDRF in combination with both of those entities about an artificial pancreas program that Insulet is interested in, as well as Animas, and both of them use our sensor as part of that effort, so --. Both -- in both relationships, a high degree of compliments.
嗯,我——對這兩家公司都非常敬重,我對兩家公司的評價都非常高。尤其是 Animas 的優秀團隊,我們每週都會會面,不論是面對面或電話會議。團隊高度整合,推動這項產品向前。他們可投入的資源比 Insulet 團隊多得多,但我們也同樣與 Insulet 積極互動。他們之前顯然——在他們推動使用 OmniPod 來投放 Ferring Labs 的一款生育用藥時,他們把重心放在那個專案上,並為此另外提交了一份 510(k),所以我認為資源配置上有些調整。但我們也在積極與他們溝通。我們與 JDRF 也曾結合這兩個實體一起討論一個 Insulet 與 Animas 都有興趣的人工胰臟計畫,而他們兩者在該項努力中都使用我們的感測器,所以——。兩段合作關係都值得高度肯定。
Operator
Operator
And that does conclude our question-and-answer session. Mr. Gregg, I'll turn the call back to you for any additional or closing comments.
以上即為我們的問答環節。Gregg 先生,我把電話交回給您,請您做任何補充或結語。
Terry Gregg - President and CEO
Terry Gregg - President and CEO
Sure. Thank you, operator. And thanks for joining us today. I just want to point out, as we look at where we've been, where we're going -- we've really had an opportunity, I think, to change the way in which folks treat diabetes today. We've done -- and the industry has done a good job, from the key opinion leaders, and now we need to take that to the next level of prescribers beyond just the endocrinology world. Internal medicine treats a large portion of this diabetes population, and that's obviously a target goal. We talked about the additions that we've added. We need to improve our marketing, messaging, and I've brought Claudia. To do that globally, we need to move into a more aggressive way, and Peter will help us in that domain, as well as others. But I really focus on what we have accomplished, based on the expenditures that we have done in the last year since I've been on board. We're third-generation filed with the FDA with clinical trial. We already have the best technology out there. I think, more importantly, as I look at the hospital sensor and our effort there, we have accomplished so much. When I came on board, it was an R&D project, and here we are planning a pivotal trial. We've been in over 100 patients now, and we've really done that on quite a limited budget. If you look at it from a global standpoint, we're really two companies. We've leveraged our technology from both the ambulatory world as well at the (inaudible) and accomplished more than other companies with far -- far greater resources that that's why we're deep in these negotiations, particularly on the hospital side.
好的。謝謝你,接線員。也謝謝各位今天加入。我只想指出,當我們回顧我們走過的路、以及我們將前往的方向——我認為我們確實有機會改變人們今天治療糖尿病的方式。我們已經——而且整個產業也做得很好,從關鍵意見領袖(KOL)開始;而現在我們需要把這件事推進到下一個層級,讓開立處方者不再只侷限於內分泌領域。內科醫師治療了相當大一部分糖尿病族群,而這顯然是我們的目標。我們談到了我們新增的人員。我們需要改善行銷與訊息傳遞,因此我找來 Claudia。要在全球做到這一點,我們需要採取更積極的方式,而 Peter 也會在那個領域以及其他方面協助我們。但我真正聚焦的是,自從我加入以來的過去一年,我們在支出規模之下所完成的成果。我們已向 FDA 申報第三代產品並進入臨床試驗。我們已經擁有市面上最好的技術。我認為更重要的是,當我看醫院用感測器以及我們在那方面的努力時,我們完成了非常多。我剛加入時,那還是一個研發專案,而現在我們正在規劃關鍵性試驗(pivotal trial)。我們目前已經在超過 100 位病患身上使用過,而且我們是在相當有限的預算下做到的。若從全球角度來看,我們其實像是兩家公司。我們把技術同時運用在院外(ambulatory)領域以及(聽不清)上,並且用遠——遠少於其他資源更充足公司的資源完成了更多,這也是為什麼我們能在談判中走得很深,尤其是在醫院端。
So I'm quite proud of where we're at. I'm quite proud of the accomplishments that we have made in this 13 months that I've been on board.
所以我對我們目前所處的位置感到非常自豪。我也對我加入以來這 13 個月我們所取得的成就感到非常自豪。
So thanks for your support and look forward to the future. Thank you, operator.
因此,謝謝各位的支持,也期待未來。謝謝你,接線員。
Operator
Operator
Okay. And thank you. That will conclude today's conference. We'd like to thank you all for your participation.
好的,謝謝。今天的電話會議到此結束。感謝各位的參與。